TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06756230

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: 8 weeks, 2 sessions per week,~Aerobic training will be provided as treadmill walking. It will be performed either downhill or on a flat treadmill, depending on the group.~Warm-up and stretching exercises~Resistance exercises will be performed with a load equivalent to 50% of 1 maximum repetition. 10 repetitions will be performed in sets, one set in each session. Based on the differences in the general condition of the patients, different workloads and modifications will be used when creating an exercise program for each patient. Resistance exercises will focus on both upper and lower extremity muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: 8 weeks, 2 sessions per week,~Aerobic training will be provided as treadmill walking. It will be performed either downhill or on a flat treadmill, depending on the group.~Warm-up and stretching exercises~Resistance exercises will be performed with a load equivalent to 50% of 1 maximum repetition. 10 repetitions will be performed in sets, one set in each session. Based on the differences in the general condition of the patients, different workloads and modifications will be used when creating an exercise program for each patient. Resistance exercises will focus on both upper and lower extremity muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Downhill Walking
Description: Treadmill exercise will be applied for 30 minutes in the target heart rate range of 60-80% intensity. The target heart rate method will be used to determine the exercise intensity. Blood pressure, heart rate and Borg Perceived Exertion Scale scores will be monitored during the exercises. Downhill walking training will continue with a constant -10% incline and will progress only with increases in speed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Walking without incline
Description: 30 minutes of progressive aerobic exercise (treadmill) will be performed in the target heart rate range of 60-80% intensity. The target heart rate method will be used to determine the exercise intensity. Blood pressure, heart rate and Borg Perceived Exertion Scale scores will be monitored during the exercises. Traditional walking training will initially involve walking with a neutral incline, and will progress with increases in speed.
Study: NCT06757855

Intervention type: DRUG
Group type: OTHER
Intervention: Olverembatinib
Description: induction therapy：40mg,QOD；~consolidation maintenance therapy: If patients with CMR are reduced to 30mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Venetoclax
Description: induction therapy：leverl 0: 100mg d-2; 200mg d-1; 400mg d1-14~leverl -1: 100mg d-2; 200mg d-1; 400mg d1-7~leverl 1: 100mg d-2; 200mg d-1; 400mg d1-21~consolidation maintenance therapy: 400mg d1-7

Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine
Description: induction therapy：75mg/m2/d, d1-7~consolidation maintenance therapy: 75mg/m2/d, d1-7
Study: NCT06753045

Intervention type: OTHER
Intervention: Smartwatch
Description: Sensors on the smartwatch will measure vitals such as heart rate, blood pressure, oxygen saturation, body composition, and electrocardio gram (ECG)

Intervention type: OTHER
Intervention: Smartwatch
Description: Sensors on the smartwatch will measure vitals such as heart rate, blood pressure, oxygen saturation, body composition, and electrocardio gram (ECG)
Study: NCT06758466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate surgery
Description: Prostate removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate surgery
Description: Prostate removal
Study: NCT06756945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily
Description: STEMI patients receive aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily
Description: STEMI patients receive aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily
Study: NCT06757257

Intervention type: DRUG
Intervention: fostamatinib
Description: oral administration
Study: NCT06756386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extra corporeal shock wave therapy (ESWT )
Description: Using wound area measurements and histological/immunohistochemical analysis of wound biopsies, we show ESWT enhanced healing of chronic ulcers associated with improved wound angiogenesis ), significantly decreased-positive macrophages per biopsy area and generally increased macrophage activity ,this activity prevent bacterial infection which delay healing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Low-level laser therapy (LLLT) has been used as an adjuvant to conventional therapy with promising results,improve healing by delivering nutrient substances , especially in patients with acute and bloody ulcers.~Positive effects include acceleration of tissue repair, increased formation of granulation tissue, wound contraction, inflammation modulation, and pain reduction The biochemical effects of LLLT are associated with the release of preformed substances (histamine, serotonin, and bradykinin), which stimulate the production of ATP and inhibit the production of prostaglandins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatments
Description: ( compression pandaging, lifestyle changes, physical activities)
Study: NCT06757517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Saline intranasal placebo comparator
Study: NCT06756919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Music therapy ( nature sounds) during the endoscopy procedure
Study: NCT06757218

Intervention type: OTHER
Group type: OTHER
Intervention: empty socket
Description: Patients will be left socket empty without any graft materials for spontaneous healing process after tooth extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Dentin Graft with Platelet Rich Fibrin
Description: Patients will be inserting autogenous dentin graft and platelet rich fibrin in the socket after extraction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous Dentin Graft with Albumin Platelet Rich Fibrin
Description: Patients will be inserting autogenous dentin graft and Albumin Platelet Rich Fibrin in the socket after extraction.
Study: NCT06758154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TXJN electro-acupuncture
Description: Firstly, EA treatment will be administered at the Neiguan (PC6, bilateral), Shenting(GV23), Yingxiang(LI20, bilateral), Yintang(GV29) acupoints. Disposable stainless-steel needles (0.25 mm × 25 mm; Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Suzhou City, China) will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensations of achiness, heaviness, and numbness (known as de qi) at all above-mentioned acupoints. Following needle manipulations, EA instruments (SDZ-V, Hwato brand, Suzhou Medical Supplies Factory Co., Ltd., Suzhou City, China) will be used to attach the needle handles at PC6, GV23, LI20, GV29, with a dilatational wave of 5 Hz and a current intensity of 2 \~ 4 mA depending on the patient's tolerance. The needles will be removed after 30 min. Participants will receive 24 sessions over 8 weeks at a frequency of 3 times per week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Firstly, EA treatment will be administered at the non-acupoints near above-mentioned real acupoints. Disposable stainless-steel needles (0.25 mm × 25 mm; Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Suzhou City, China) will be used. After skin disinfection, the acupuncturists will take the needle into the acupoints without the sensations of de qi. Following needle manipulations, EA instruments (SDZ-V, Hwato brand, Suzhou Medical Supplies Factory Co., Ltd., Suzhou City, China) will be used to attach the needle handles at non-acupoints without the current. The needles will be removed after 30 min. Participants will receive 24 sessions over 8 weeks at a frequency of 3 times per week.
Study: NCT06756529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand massage
Description: Hand massage was applied to the patients before surgery, on the morning of surgery and after surgery.
Study: NCT06757660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Furcation Repair
Description: to evaluate the clinical and radiographic effects of chitosan and Naocl as an irrigation protocols applied during repair of furcation perforation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Furcation Repair
Description: to evaluate the clinical and radiographic effects of chitosan and Naocl as an irrigation protocols applied during repair of furcation perforation.
Study: NCT06757374

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resistin
Description: Considering the HG effect on endocrinologic and metabolic complications, resistin levels in maternal serum may change in the presence of HG severity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resistin
Description: Considering the HG effect on endocrinologic and metabolic complications, resistin levels in maternal serum may change in the presence of HG severity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resistin
Description: Considering the HG effect on endocrinologic and metabolic complications, resistin levels in maternal serum may change in the presence of HG severity
Study: NCT06512051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin
Description: Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin
Study: NCT06534918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
Study: NCT06348147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a CD38-directed cytolytic antibody indicated for the treatment of adults with multiple myeloma. 1800 mg will be given subcutaneously according to its standard package insert schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered, once daily orally on Days 1-21 of a 28-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma, will be given subcutaneously once weekly on days 1, 8, and 15 of every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is a glucocorticoid.
Study: NCT04280523

Intervention type: DRUG
Intervention: ESR-specific PET scan
Description: Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level \[estradiol (E2)\], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1\~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
Study: NCT06534918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Course
Description: The virtual, synchronous nutrition course will be a 30-60 minute group education class on nutrition information for cancer survivors. The class will be held once per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Course
Description: The virtual, synchronous nutrition course will be a 30-60 minute group education class on nutrition information for cancer survivors. The class will be held once per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Course
Description: The virtual, synchronous nutrition course will be a 30-60 minute group education class on nutrition information for cancer survivors. The class will be held once per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Description: The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly One on One Session with Registered Dietitian
Description: Participants will be referred to weekly one on one sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly One on One Session with an Exercise Physiologist
Description: Participants will be referred to weekly one on one sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Prescription
Description: The nutrition prescription pad serves as a quick checklist designed to assist participants in effectively monitoring their dietary habits. Participants randomized to intervention group will each receive a one-time nutrition prescription in person during their first intervention week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Prescription
Description: The physical activity prescription pad serves as a quick checklist designed to assist participants in effectively monitoring their exercise routines. Participants randomized to intervention group will each receive a one-time physical prescription in person during their first intervention week.
Study: NCT06306222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser lithotripsy
Description: Ureteroscopic laser lithotripsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser lithotripsy
Description: Ureteroscopic laser lithotripsy
Study: NCT04768556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG experimental sessions 1
Description: An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.

Intervention type: OTHER
Group type: OTHER
Intervention: EEG experimental sessions 1
Description: An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.

Intervention type: OTHER
Group type: OTHER
Intervention: EEG experimental sessions 1
Description: An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG experimental sessions 2
Description: An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action

Intervention type: OTHER
Group type: OTHER
Intervention: EEG experimental sessions 2
Description: An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action

Intervention type: OTHER
Group type: OTHER
Intervention: EEG experimental sessions 2
Description: An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
Study: NCT05082688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccination (Shingrix, GSK)
Description: Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccination (Shingrix, GSK)
Description: Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)
Description: Fluarix Tetra is a quadrivalent inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)
Description: Fluarix Tetra is a quadrivalent inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study: NCT05908227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHF high
Description: Nasal high flow therapy 8L/min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHF low
Description: Nasal high flow therapy 6L/min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: Nasal continuous positive airway pressure 6 cm H20
Study: NCT05304897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP treatment
Description: PRP treatment for bronchopleural fistula
Study: NCT05726097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: colonic preparation
Study: NCT06031441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7566802
Description: RO7566802 solution for infusion will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7566802
Description: RO7566802 solution for infusion will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab solution for infusion will be administered as specified in each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab solution for infusion will be administered as specified in each treatment arm.
Study: NCT05726097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium phosphate
Description: colonic preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol + ascorbic acid
Description: colonic preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol + ascorbic acid
Description: colonic preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gastrografin
Description: colonic preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gastrografin
Description: colonic preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesiumoxid + sodium picosulfate
Description: colonic preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesiumoxid + sodium picosulfate
Description: colonic preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: colonic preparation
Study: NCT06173622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fetal Positioning
Description: In the study, venipuncture was applied to the intervention and control groups. While the procedure was performed by an experienced neonatal nurse, the neonates' pain score, crying duration and physiological parameters were monitored by another researcher (observer).
Study: NCT05967273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CirrhosisRx CDS
Description: CirrhosisRx is a cirrhosis-specific CDS that organizes clinical data into clinically relevant groupings and links them to order sets consistent with national practice guidelines for inpatient cirrhosis care.
Study: NCT04852523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: 18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.